Fig. 2.

Treatment comparison (PF-06439535 group vs bevacizumab-EU group) for ORR, based on responses achieved by week 19 and confirmed by week 25 in the intent-to-treat population. Panel a depicts the unstratified ORR risk ratio with 90% and 95% CIs, and panel b depicts the unstratified ORR risk difference with 95% CI. Dashed lines indicate equivalence margins agreed with regulatory authorities in the EU, Japan, or the US. Data cutoff date 8 May 2017. Analyses based on 2-sided Miettinen and Nurminen method without stratification variables. Bevacizumab-EU reference bevacizumab sourced from the European Union, CI confidence interval, ORR objective response rate